Compare Incyte Corporation (INCY) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SoFi Technologies Inc — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while SoFi Technologies Inc trades at $17.91 (market cap $23.22B). The key difference: Incyte Corporation and SoFi Technologies Inc are close in size by market cap, and Incyte Corporation is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals.
| INCY | SOFI | |
|---|---|---|
Market Cap | $24.54B | $23.22B |
Sector | Health | Financials |
52-Week High | $129.93 | $32.21 |
52-Week Low | $81.61 | $15.15 |
Enterprise Value | $20.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
SOFI stock trades at $18.02, down 0.55% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company reported strong Q2 2026 results, beating EPS estimates with 40% year-over-year adjusted net revenue growth and record loan originations. Revenue guidance for 2026 was raised to $4.75-$4.85 billion. The stock is trading below the consensus price target of $19.50, with analyst sentiment mixed but leaning positive.
The outlook for SOFI is supported by robust member growth and a diversified revenue stream, though risks include dependence on lending growth and potential interest rate sensitivity. The current valuation at a P/E of 36.69 and P/S of 5.6 reflects high growth expectations. Upside potential exists if execution continues, but investors should weigh the premium valuation against competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
